

Trulicity (dulaglutide)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION	
LAST NAME:	FIRST NAME:
PHONE NUMBER:	DATE OF BIRTH:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
PATIENT INSURANCE ID NUMBER:	

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page



Trulicity (dulaglutide)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?		
<input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Type II diabetes <input type="checkbox"/> Type II diabetes with established cardiovascular disease <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s):		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Is patient going to be using drug in combination with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No Lab Values: Was the patient's most recent HbA1c in the past 6 months or prior to starting the requested medication 7.0% or greater? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation of HbA1c level required.</i> Is the patient's estimated glomerular filtration rate (GFR) less than or equal to 45 mL/min/1.73 m ² ? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation of GFR required.</i> Does the patient currently have a serum creatinine level exceeding 1.8 mg/dL or an estimated GFR less than 30 mL/min/1.73 m ² ? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation required.</i>		
Clinical Information: Has the patient tried or is the patient currently taking metformin? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation required.</i> Has treatment with metformin been avoided due to lactic acidosis or elevated liver enzymes? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation required.</i> Does the patient have advanced liver disease with at least one of the following? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Documentation required.</i> If <u>yes</u> , please select: <input type="checkbox"/> Ascites <input type="checkbox"/> Cirrhosis <input type="checkbox"/> Hepatic encephalopathy <input type="checkbox"/> Portal hypertension		

Trulicity (dulaglutide)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Has the patient had a 3-month trial with either generic exenatide or liraglutide ? Yes No
Documentation required.

If patient has used either generic exenatide or liraglutide, did patient reach their HbA1C goal of less than 7%? Yes No *Documentation required.*

Does patient have an absolute contraindication to both generic exenatide AND liraglutide? Yes No *Documentation required.*

Is the patient currently taking any of the following medications? Yes No

If yes, please select:

- Janumet/Janumet XR (sitagliptin/metformin)
- Januvia (sitagliptin)
- Jentadueto/Jentadueto XR (linagliptin/metformin)
- Kazano (alogliptin/metformin)
- Kombiglyze XR (saxagliptin/metformin)
- Nesina (alogliptin)
- Onglyza (saxagliptin)
- Oseni (alogliptin/pioglitazone)
- Tradjenta (linagliptin)
- Glyxambi (empagliflozin/linagliptin)
- Seglujan (ertugliflozin/sitagliptin)
- Qtern (dapagliflozin/saxagliptin)

If the patient is taking any of the above medications, will concomitant therapy with those medications be discontinued? Yes No

Type II diabetes with established cardiovascular disease:

Is the most recent HgbA1c in the past 6months, prior to starting the requested GLP-1 product 9.5% or less? Yes No *Documentation required.*

Is patient 50 years of age or older with established cardiovascular disease, (previous cardiovascular disease, cerebrovascular disease, or peripheral vascular disease)? Yes No *Documentation required.*

Please check at least one of the following with documentation in submitted chart notes:

- History of MI or stroke or transient ischemic attack
- History of unstable angina with ECG changes
- History of coronary revascularization procedure
- History of carotid revascularization procedure
- History of peripheral revascularization procedure
- History of symptomatic coronary heart disease documented by positive stress test, or cardiac imaging
- Patient has more than 50% stenosis on angiography or imaging of coronary, carotid or lower extremities arteries
- Patient has asymptomatic cardiac ischemia documented by positive nuclear imaging test or exercise test or stress echo or any cardiac imaging

Trulicity (dulaglutide)
Prior Authorization Request Form
Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

- Patient has chronic heart failure NYHA class II or III
- Chronic renal impairment documented by eGFR below 60ml/min/1.73m² per modification of diet in renal disease (MDRD)

Is patient 55 to 59 years of age, inclusive, with subclinical vascular disease? Yes No
Documentation required.

Please check at least one of the following with documentation in submitted chart notes:

- myocardial ischemia,
- coronary, carotid, or lower extremity artery stenosis exceeding 50%,
- left ventricular hypertrophy,
- estimated glomerular filtration rate (eGFR) less than 60 mL/min per 1.73 m², or
- albuminuria

Is patient age 60 years or older AND has at least 2 or more of the following risk factors? Yes No
Documentation required.

Please check at least two of the following with documentation in submitted chart notes:

- tobacco use,
- dyslipidemia,
- hypertension, or
- abdominal obesity

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909